Long-Term Safety, Outcome, and Clinical Effects of Subcutaneous and Intravenous Treprostinil Treatment in Patients with Severe Chronic Pulmonary Arterial Hypertension

曲前列环素 医学 肺动脉高压 不利影响 肺移植 内科学 肺功能测试 移植 外科 麻醉
作者
Satenik Harutyunova,Nicola Benjamin,Christina A. Eichstaedt,Alberto Maria Marra,Panagiota Xanthouli,Christian Nagel,Ekkehard Grünig,Benjamin Egenlauf
出处
期刊:Respiration [Karger Publishers]
卷期号:102 (8): 579-590 被引量:5
标识
DOI:10.1159/000531169
摘要

BACKGROUND: Current guidelines recommend treatment with parenteral prostacyclin analogs in patients with severe pulmonary arterial hypertension (PAH), who have insufficient response to treatment. Real-life data are sought to help physicians in treatment decisions and clinical care of patients. OBJECTIVE: This study analyzed safety, clinical effects, and long-term outcomes of subcutaneous (sc) and/or intravenous (iv) treprostinil via different pump systems in consecutive patients with PAH. METHODS: Thirty-seven patients with severe progressive PAH despite dual combination therapy (20 female, mean age: 52.3 ± 15 years, mean pulmonary vascular resistance: 12.1 ± 5.1 WU) were initiated with add-on treprostinil sc and were routinely clinically assessed. Changes in clinical parameters, adverse events, and outcome were analyzed retrospectively. RESULTS: In 24 of 37 patients, treprostinil administration was continued iv via implantation of LENUS Pro® pump after 3 ± 1.3 months, 6 patients continued with sc therapy, and 7 discontinued treatment. After 3, 6, 9, and 12 months of treprostinil treatment, patients showed a significant improvement in mean 6-min walk distance and tricuspid annular plane systolic excursion compared to baseline. In 8 of the 24 patients, iv pumps required surgical revision. During a mean follow-up of 2.82 ± 1.95 years, 12 patients died, four received lung transplantation. Transplant-free survival after 1, 2, and 3 years was 85.7%, 69.2%, and 65.3%, respectively. CONCLUSION: sc treprostinil as add-on to double combination treatment significantly improved exercise capacity and right heart function. In most patients, treprostinil could be continued via more tolerable iv administration approach (LENUS Pro® pump), showing reasonable overall survival with respect to the severity of PAH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美味又健康完成签到 ,获得积分10
1秒前
forktail完成签到,获得积分10
3秒前
大模型的应助被乔治采纳,获得10
3秒前
海盐芝士完成签到,获得积分10
4秒前
hurys的应助被麻瓜采纳,获得50
4秒前
shgong发布了新的文献求助20
5秒前
852的应助被麻瓜采纳,获得10
5秒前
wenhao完成签到 ,获得积分10
5秒前
Akim的应助被coco采纳,获得10
6秒前
植柏完成签到,获得积分10
6秒前
数学情缘完成签到,获得积分10
6秒前
7秒前
7秒前
小豆包完成签到,获得积分10
8秒前
Bloo完成签到,获得积分10
8秒前
lyq完成签到,获得积分10
9秒前
拾柒完成签到 ,获得积分10
9秒前
10秒前
10秒前
不能没有科研完成签到,获得积分10
13秒前
荣荣发布了新的文献求助10
13秒前
13秒前
十二完成签到,获得积分10
14秒前
14秒前
小杨肉串完成签到,获得积分10
14秒前
十八完成签到,获得积分10
15秒前
Jasper的应助被shgong采纳,获得10
15秒前
16秒前
我是老大的应助被大头采纳,获得10
16秒前
hqlran完成签到,获得积分10
17秒前
玄魁完成签到,获得积分10
17秒前
18秒前
魔幻飞风发布了新的文献求助10
18秒前
科学家完成签到,获得积分10
19秒前
柠檬水完成签到,获得积分10
19秒前
天天向上的应助被小小昌采纳,获得10
20秒前
20秒前
yuyuhong完成签到,获得积分10
21秒前
Jade完成签到 ,获得积分10
22秒前
qiao完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614